Literature DB >> 19148132

Reduced proliferation of CD34(+) cells from patients with acute myeloid leukemia after gene transfer of INPP5D.

A Metzner1, C Precht, B Fehse, W Fiedler, C Stocking, A Günther, G W Mayr, M Jücker.   

Abstract

Acute myeloid leukemia (AML) is a malignant disease characterized by deregulated proliferation of immature myeloid cells. Constitutive activation of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently detected in approximately 50-70% of AML patients. The gene INPP5D encodes the SH2-containing inositol 5-phosphatase 1 (SHIP1), which is a negative regulator of PI3K/AKT signaling. After lentiviral-mediated gene transfer of INPP5D into CD34(+) cells derived from AML patients (n=12) the granulocyte macrophage-colony stimulating factor (GM-CSF)-dependent proliferation was reduced in all samples analyzed (average 86%; range 72-93%). An enzymatically inactive form of SHIP1 (D672A) had no effect. In addition, SHIP1 reduced the autonomous proliferation of CD34(+) cells from a patient with a secondary AML who had a very high peripheral blast count (300 x 10(9) l(-1)). These data show that SHIP1 can effectively block GM-CSF-dependent and autonomous proliferation of AML cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19148132     DOI: 10.1038/gt.2008.184

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  8 in total

Review 1.  Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.

Authors:  Sophie Park; Nicolas Chapuis; Jérôme Tamburini; Valérie Bardet; Pascale Cornillet-Lefebvre; Lise Willems; Alexa Green; Patrick Mayeux; Catherine Lacombe; Didier Bouscary
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

2.  The tumor suppressor SHIP1 colocalizes in nucleolar cavities with p53 and components of PML nuclear bodies.

Authors:  Patrick Ehm; Marcus M Nalaskowski; Torsten Wundenberg; Manfred Jücker
Journal:  Nucleus       Date:  2015-02-27       Impact factor: 4.197

3.  Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.

Authors:  J Khalife; H S Radomska; R Santhanam; X Huang; P Neviani; J Saultz; H Wang; Y-Z Wu; H Alachkar; M Anghelina; A Dorrance; J Curfman; C D Bloomfield; B C Medeiros; D Perrotti; L J Lee; R J Lee; M A Caligiuri; F Pichiorri; C M Croce; R Garzon; M L Guzman; J H Mendler; G Marcucci
Journal:  Leukemia       Date:  2015-05-14       Impact factor: 11.528

4.  SHIP1, but not an AML-derived SHIP1 mutant, suppresses myeloid leukemia growth in a xenotransplantation mouse model.

Authors:  M Täger; S Horn; E Latuske; P Ehm; M Schaks; M Nalaskowski; B Fehse; W Fiedler; C Stocking; J Wellbrock; M Jücker
Journal:  Gene Ther       Date:  2017-11-16       Impact factor: 5.250

5.  The effect of the top 20 Alzheimer disease risk genes on gray-matter density and FDG PET brain metabolism.

Authors:  Eddie Stage; Tugce Duran; Shannon L Risacher; Naira Goukasian; Triet M Do; John D West; Holly Wilhalme; Kwangsik Nho; Meredith Phillips; David Elashoff; Andrew J Saykin; Liana G Apostolova
Journal:  Alzheimers Dement (Amst)       Date:  2016-12-19

Review 6.  Strategy for Leukemia Treatment Targeting SHP-1,2 and SHIP.

Authors:  Fang Hao; Chen Wang; Christine Sholy; Min Cao; Xunlei Kang
Journal:  Front Cell Dev Biol       Date:  2021-08-19

7.  Expressional alterations in functional ultra-conserved non-coding RNAs in response to all-trans retinoic acid--induced differentiation in neuroblastoma cells.

Authors:  Karen M Watters; Kenneth Bryan; Niamh H Foley; Maria Meehan; Raymond L Stallings
Journal:  BMC Cancer       Date:  2013-04-08       Impact factor: 4.430

Review 8.  Late-Onset Alzheimer's Disease Genes and the Potentially Implicated Pathways.

Authors:  Samantha L Rosenthal; M Ilyas Kamboh
Journal:  Curr Genet Med Rep       Date:  2014-03-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.